Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Rituximab in Dermatomyositis

Study Title:

An open label trial to evaluate the safety and efficacy of rituximab in the treatment of patients with dermatomyositis

Principal Investigator:

David Fiorentino, M.D., Ph.D.

Study Hypothesis:

B cell depletion with Rituximab will be safe and effective therapy for skin and muscle inflammation in patients with dermatomyositis

Study Design:

Open label, single center, pilot study

Types & Number of IIM Studied:

8 adult dermatomyositis patients

Entry Criteria:

  • Diagnosis of probable or definite dermatomyositis by Bohan/Peter criteria (Bohan and Peter 1975), including classic dermatologic features defined by Sontheimer's criteria
  • Active muscle disease with either elevated laboratory markers of muscle breakdown (ie. CPK >400 U/L or aldolase >8 U/L) OR a MMT modified MRC score of <85
  • Active skin disease with s DSSI>2

IMACS Core Set Measures Included:

Physician Global Activity-VAS, Patient Global Activity-VAS, Muscle Strength Testing-MMT, Functional Assessment Tools-HAQ, Laboratory-Muscle Enzymes, Extramuscular Assessment-Myositis Disease Activity Assessment Tool (MDAAT)

Other Measures Included:

Patient Pruritus Assessment, Dermatomyositis Skin Severity Index (DSSI), Skin photographs, CD19 B cell level, Safety laboratory measures (CBC, CMP, Urinalysis)

Primary Outcome:

  • Safety Endpoints
    • Incidence of treatment emergent adverse events (AE's) including infections, infusion reactions and disease progression.
    • Safety assessment will include physical examination with vital signs, routine blood work (hematology and chemistry) and immunological testing.
  • Primary Efficacy Endpoint: Partial remission (PR) at 24 weeks, defined as:
    • At least a 50% reduction in creatine phosphokinase (CPK) if baseline values are >2x upper limits of normal OR
    • o 50% improvement of manual muscle strength test (MMT) using the modified Medical Research Council (MRC) scale (Daniels and Worthingham 1972), defined as a 50% reduction in the difference between maximum strength (score of 90) and the patient's baseline score (if baseline score is <85) OR
    • 75% reduction in cutaneous lesions using the Dermatomyositis Skin Severity Index (DSSI) if baseline score is > 2

Key Trial Dates:

Start of Enrollment - 12/17/2004
Study Completion - 8/28/2007

Funding Sources:

Genentech, Inc.


Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis., Arch Dermatol, 2007 Jun;143(6):763-7. [Abstract Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis., Arch Dermatol, 2007 Jun;143(6):763-7.]


David Fiorentino, M.D., Ph.D.
Assistant Professor of Dermatology
Stanford University School of Medicine
North Campus Outpatient Center
450 Broadway, C-234
Redwood City, CA 94063
Tel 650-721-7160
to Top